speb/financial-data huggingface dataset:
PCRX balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 484615000.00
PCRX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 17363000.00
PCRX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -83276000.00
PCRX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 189389000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Account Payable: 3084000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 14434000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Inventory: -20929000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 2714000.00
PCRX cash_flow (quarterly, 2024-12-31) — Change In Other Current Liabilities: 3909000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Payable: 3084000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 17518000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 61000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Receivables: -7748000.00
PCRX cash_flow (annual, 2024-12-31) — Change In Working Capital: -11098000.00
PCRX cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -7748000.00
PCRX cash_flow (annual, 2024-12-31) — Changes In Cash: 123476000.00
PCRX balance_sheet (annual, 2024-12-31) — Common Stock: 47000.00
PCRX balance_sheet (annual, 2024-12-31) — Common Stock Equity: 778348000.00
PCRX cash_flow (annual, 2024-12-31) — Common Stock Payments: -25000000.00
PCRX balance_sheet (annual, 2024-12-31) — Construction In Progress: 27996000.00
PCRX income_statement (annual, 2024-12-31) — Cost Of Revenue: 170428000.00
PCRX balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 51313000.00
PCRX balance_sheet (annual, 2024-12-31) — Current Assets: 745130000.00
PCRX balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 8887000.00
PCRX balance_sheet (annual, 2024-12-31) — Current Debt: 201776000.00
PCRX balance_sheet (quarterly, 2024-12-31) — Current Debt: 201776000.00
PCRX balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 210663000.00
PCRX balance_sheet (annual, 2024-12-31) — Current Liabilities: 309920000.00
PCRX cash_flow (annual, 2024-12-31) — Deferred Income Tax: 20621000.00
PCRX cash_flow (annual, 2024-12-31) — Deferred Tax: 20621000.00
PCRX cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 78785000.00
PCRX income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 57288000.00
PCRX cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 78785000.00
PCRX income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 57288000.00
PCRX income_statement (annual, 2024-12-31) — Diluted Average Shares: 46245000.00
PCRX income_statement (annual, 2024-12-31) — Diluted EPS: -2.15
PCRX income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -99560000.00
PCRX income_statement (annual, 2024-12-31) — EBIT: -49667000.00
PCRX income_statement (annual, 2024-12-31) — EBITDA: 29118000.00
PCRX cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 0.00
PCRX cash_flow (annual, 2024-12-31) — End Cash Position: 276774000.00
PCRX cash_flow (annual, 2024-12-31) — Financing Cash Flow: 17363000.00
PCRX balance_sheet (annual, 2024-12-31) — Finished Goods: 47098000.00
PCRX cash_flow (annual, 2024-12-31) — Free Cash Flow: 178753000.00
PCRX balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 343000.00
PCRX income_statement (annual, 2024-12-31) — General And Administrative Expense: 122084000.00
PCRX balance_sheet (annual, 2024-12-31) — Goodwill: 0.00
PCRX balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 425970000.00
PCRX balance_sheet (annual, 2024-12-31) — Gross PPE: 349320000.00
PCRX income_statement (annual, 2024-12-31) — Gross Profit: 530538000.00
PCRX income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 163243000.00
PCRX income_statement (quarterly, 2024-12-31) — Impairment Of Capital Assets: 0.00
PCRX cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 11021000.00
PCRX cash_flow (quarterly, 2024-12-31) — Income Tax Paid Supplemental Data: 1446000.00
PCRX income_statement (annual, 2024-12-31) — Interest Expense: 13439000.00
PCRX income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 13439000.00
PCRX income_statement (annual, 2024-12-31) — Interest Income: 19689000.00
PCRX income_statement (annual, 2024-12-31) — Interest Income Non Operating: 19689000.00
PCRX cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 15418000.00
PCRX balance_sheet (annual, 2024-12-31) — Interest Payable: 1418000.00
PCRX balance_sheet (quarterly, 2024-12-31) — Interest Payable: 1418000.00
PCRX balance_sheet (annual, 2024-12-31) — Inventory: 125282000.00
PCRX balance_sheet (annual, 2024-12-31) — Invested Capital: 1363669000.00
PCRX cash_flow (annual, 2024-12-31) — Investing Cash Flow: -83276000.00
PCRX balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 0.00
PCRX balance_sheet (quarterly, 2024-12-31) — Investmentin Financial Assets: 0.00
PCRX balance_sheet (annual, 2024-12-31) — Investments And Advances: 0.00
PCRX balance_sheet (quarterly, 2024-12-31) — Investments And Advances: 0.00
PCRX cash_flow (annual, 2024-12-31) — Issuance Of Debt: 287500000.00
PCRX cash_flow (quarterly, 2024-12-31) — Issuance Of Debt: 0.00
PCRX balance_sheet (annual, 2024-12-31) — Leases: 86034000.00
PCRX balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 44645000.00
PCRX balance_sheet (annual, 2024-12-31) — Long Term Debt: 383545000.00
PCRX balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 428190000.00
PCRX cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 287500000.00
PCRX cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 0.00
PCRX cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -210885000.00
PCRX balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 186068000.00
PCRX cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
PCRX cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -25000000.00
PCRX balance_sheet (annual, 2024-12-31) — Net Debt: 308547000.00
PCRX income_statement (annual, 2024-12-31) — Net Income: -99560000.00
PCRX income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -99560000.00
PCRX income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -99560000.00
PCRX income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -99560000.00
PCRX income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -99560000.00
PCRX cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -99560000.00
PCRX income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -99560000.00
PCRX income_statement (annual, 2024-12-31) — Net Interest Income: 3120000.00
PCRX cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -72640000.00
PCRX cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 76615000.00
PCRX cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: 76615000.00
PCRX income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 3120000.00
PCRX cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -9841000.00
PCRX balance_sheet (annual, 2024-12-31) — Net PPE: 216391000.00
PCRX cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -10636000.00
PCRX balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 352378000.00
PCRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 130376000.00
PCRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 0.00
PCRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 130376000.00
PCRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 0.00
PCRX income_statement (annual, 2024-12-31) — Normalized EBITDA: 184843000.00
PCRX income_statement (annual, 2024-12-31) — Normalized Income: 23462750.00
PCRX cash_flow (annual, 2024-12-31) — Operating Cash Flow: 189389000.00
PCRX cash_flow (annual, 2024-12-31) — Operating Gains Losses: -7518000.00
PCRX cash_flow (quarterly, 2024-12-31) — Operating Gains Losses: 0.00
PCRX income_statement (annual, 2024-12-31) — Operating Income: 89872000.00
PCRX income_statement (annual, 2024-12-31) — Operating Revenue: 700966000.00
PCRX balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 46240604.00
PCRX balance_sheet (annual, 2024-12-31) — Other Current Assets: 21929000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 201776000.00
PCRX balance_sheet (quarterly, 2024-12-31) — Other Current Borrowings: 201776000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 343000.00
PCRX income_statement (annual, 2024-12-31) — Other Gand A: 87227000.00
PCRX income_statement (annual, 2024-12-31) — Other Income Expense: -156098000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 425970000.00
PCRX cash_flow (annual, 2024-12-31) — Other Non Cash Items: -6255000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 35649000.00
PCRX balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: 35649000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 37058000.00
PCRX income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -373000.00
PCRX income_statement (annual, 2024-12-31) — Other Operating Expenses: 7702000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Properties: 49222000.00
PCRX balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 207841000.00
PCRX income_statement (annual, 2024-12-31) — Other Special Charges: -7518000.00
PCRX income_statement (quarterly, 2024-12-31) — Other Special Charges: 0.00
PCRX balance_sheet (annual, 2024-12-31) — Payables: 19133000.00
PCRX balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 70446000.00
PCRX balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 28811000.00
PCRX balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 28811000.00
PCRX balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
PCRX income_statement (annual, 2024-12-31) — Pretax Income: -63106000.00
PCRX cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: -24411000.00
PCRX balance_sheet (annual, 2024-12-31) — Properties: 0.00
PCRX cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
PCRX cash_flow (annual, 2024-12-31) — Purchase Of Investment: -252212000.00
PCRX cash_flow (annual, 2024-12-31) — Purchase Of PPE: -10636000.00
PCRX balance_sheet (annual, 2024-12-31) — Raw Materials: 50800000.00
PCRX balance_sheet (annual, 2024-12-31) — Receivables: 113304000.00
PCRX income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 148931000.00
PCRX income_statement (annual, 2024-12-31) — Reconciled Depreciation: 78785000.00
PCRX cash_flow (annual, 2024-12-31) — Repayment Of Debt: -210885000.00
PCRX cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -25000000.00
PCRX income_statement (annual, 2024-12-31) — Research And Development: 81577000.00
PCRX income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 7702000.00
PCRX balance_sheet (annual, 2024-12-31) — Retained Earnings: -206356000.00
PCRX income_statement (annual, 2024-12-31) — Salaries And Wages: 34857000.00
PCRX cash_flow (annual, 2024-12-31) — Sale Of Investment: 179572000.00
PCRX income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 172015000.00
PCRX income_statement (annual, 2024-12-31) — Selling General And Administration: 294099000.00
PCRX balance_sheet (annual, 2024-12-31) — Share Issued: 47077844.00
PCRX income_statement (annual, 2024-12-31) — Special Income Charges: -155725000.00
PCRX cash_flow (annual, 2024-12-31) — Stock Based Compensation: 51171000.00
PCRX balance_sheet (annual, 2024-12-31) — Stockholders Equity: 778348000.00
PCRX balance_sheet (annual, 2024-12-31) — Tangible Book Value: 352378000.00
PCRX income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -32702250.00
PCRX income_statement (annual, 2024-12-31) — Tax Provision: 36454000.00
PCRX income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
PCRX balance_sheet (annual, 2024-12-31) — Total Assets: 1553516000.00
PCRX balance_sheet (annual, 2024-12-31) — Total Capitalization: 1161893000.00
PCRX balance_sheet (annual, 2024-12-31) — Total Debt: 638853000.00
PCRX balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 778348000.00
PCRX income_statement (annual, 2024-12-31) — Total Expenses: 611094000.00
PCRX balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 775168000.00
PCRX balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 808386000.00
PCRX balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 465248000.00
PCRX income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -73371000.00
PCRX income_statement (annual, 2024-12-31) — Total Other Finance Cost: 3130000.00
PCRX income_statement (annual, 2024-12-31) — Total Unusual Items: -155725000.00
PCRX income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -155725000.00
PCRX balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 837240.00
PCRX balance_sheet (annual, 2024-12-31) — Treasury Stock: 25121000.00
PCRX balance_sheet (annual, 2024-12-31) — Work In Process: 27384000.00
PCRX balance_sheet (annual, 2024-12-31) — Working Capital: 435210000.00
PCRX income_statement (quarterly, 2025-03-31) — +Operating Expense: 126440000.00
PCRX income_statement (quarterly, 2025-03-31) — +Total Revenue: 168923000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 23172000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 104745000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -139775000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1023808000.00
PCRX income_statement (quarterly, 2025-03-31) — Amortization: 14322000.00
PCRX income_statement (quarterly, 2025-03-31) — Amortization Of Intangibles Income Statement: 14322000.00
PCRX income_statement (quarterly, 2025-03-31) — Average Dilution Earnings: 0.00
PCRX income_statement (quarterly, 2025-03-31) — Basic Average Shares: 46275000.00
PCRX income_statement (quarterly, 2025-03-31) — Basic EPS: 0.10
PCRX cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 276774000.00
PCRX cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -8548000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 53083000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Capital Stock: 47000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 283610000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 493626000.00
PCRX cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -2994000.00
PCRX cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -25629000.00
PCRX cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 35459000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 2464000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: 4702000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Inventory: -8472000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: 1082000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Payable: 2464000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 7166000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -5201000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Receivables: 8559000.00
PCRX cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 3134000.00
PCRX cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 8559000.00
PCRX cash_flow (quarterly, 2025-03-31) — Changes In Cash: 6836000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Common Stock: 47000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 798541000.00
PCRX cash_flow (quarterly, 2025-03-31) — Common Stock Payments: 0.00
PCRX balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 30529000.00
PCRX income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 34306000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 80069000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Current Assets: 759962000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 9405000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Current Debt: 202086000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 211491000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 314732000.00
PCRX cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: 1397000.00
PCRX cash_flow (quarterly, 2025-03-31) — Deferred Tax: 1397000.00
PCRX cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 21168000.00
PCRX income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 14322000.00
PCRX cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 21168000.00
PCRX income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 14322000.00
PCRX income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 46526000.00
PCRX income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.10
PCRX income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — EBIT: 12441000.00
PCRX income_statement (quarterly, 2025-03-31) — EBITDA: 33609000.00
PCRX cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 0.00
PCRX cash_flow (quarterly, 2025-03-31) — End Cash Position: 283610000.00
PCRX cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -2994000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Finished Goods: 55584000.00
PCRX cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 26911000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 1351000.00
PCRX income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 31205000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Goodwill: 21520000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 456489000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Gross PPE: 352954000.00
PCRX income_statement (quarterly, 2025-03-31) — Gross Profit: 134617000.00
PCRX cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 286000.00
PCRX income_statement (quarterly, 2025-03-31) — Interest Expense: 3735000.00
PCRX income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 3735000.00
PCRX income_statement (quarterly, 2025-03-31) — Interest Income: 6895000.00
PCRX income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 6895000.00
PCRX cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 2715000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Inventory: 133754000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Invested Capital: 1381917000.00
PCRX cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -25629000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 28031000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Leases: 86663000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 43678000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 381290000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 424968000.00
PCRX cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -2813000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 187034000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -16702000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
PCRX balance_sheet (quarterly, 2025-03-31) — Net Debt: 299766000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Income: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 4812000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 4812000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Interest Income: 2315000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -379000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -2813000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -2813000.00
PCRX income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 2315000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -181000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Net PPE: 213179000.00
PCRX cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -8548000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 342052000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 129008000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 6996000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 129008000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 6996000.00
PCRX income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 39796000.00
PCRX income_statement (quarterly, 2025-03-31) — Normalized Income: 9699730.00
PCRX cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 35459000.00
PCRX income_statement (quarterly, 2025-03-31) — Operating Income: 8177000.00
PCRX income_statement (quarterly, 2025-03-31) — Operating Revenue: 168923000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 46283407.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 27837000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 202086000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 1351000.00
PCRX income_statement (quarterly, 2025-03-31) — Other Gand A: 20609000.00
PCRX income_statement (quarterly, 2025-03-31) — Other Income Expense: -1786000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 434969000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Investments: 28031000.00
PCRX cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: -9605000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 28031000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 41432000.00
PCRX income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 4401000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Properties: 48728000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 210016000.00
PCRX income_statement (quarterly, 2025-03-31) — Other Special Charges: 7000000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Payables: 23172000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 103241000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
PCRX income_statement (quarterly, 2025-03-31) — Pretax Income: 8706000.00
PCRX cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
PCRX balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
PCRX cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -16702000.00
PCRX cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -69629000.00
PCRX cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -8548000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Raw Materials: 45890000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Receivables: 104745000.00
PCRX income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 27460000.00
PCRX income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 21168000.00
PCRX cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -2813000.00
PCRX cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: 0.00
PCRX income_statement (quarterly, 2025-03-31) — Research And Development: 25342000.00
PCRX income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: -813000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -201544000.00
PCRX income_statement (quarterly, 2025-03-31) — Salaries And Wages: 10596000.00
PCRX cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 69250000.00
PCRX income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 55571000.00
PCRX income_statement (quarterly, 2025-03-31) — Selling General And Administration: 86776000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Share Issued: 47120647.00
PCRX income_statement (quarterly, 2025-03-31) — Special Income Charges: -6187000.00
PCRX cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 14553000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 798541000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 342052000.00
PCRX income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -1299270.00
PCRX income_statement (quarterly, 2025-03-31) — Tax Provision: 3894000.00
PCRX income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
PCRX balance_sheet (quarterly, 2025-03-31) — Total Assets: 1586669000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 1179831000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Total Debt: 636459000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 798541000.00
PCRX income_statement (quarterly, 2025-03-31) — Total Expenses: 160746000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 788128000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 826707000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 473396000.00
PCRX income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 1990000.00
PCRX income_statement (quarterly, 2025-03-31) — Total Other Finance Cost: 845000.00
PCRX income_statement (quarterly, 2025-03-31) — Total Unusual Items: -6187000.00
PCRX income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -6187000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 837240.00
PCRX balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 25121000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Work In Process: 32280000.00
PCRX balance_sheet (quarterly, 2025-03-31) — Working Capital: 445230000.00
PCRX income_statement (quarterly, 2025-06-30) — +Operating Expense: 131100000.00
PCRX income_statement (quarterly, 2025-06-30) — +Total Revenue: 181099000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 30124000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 114367000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -152775000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1035563000.00
PCRX income_statement (quarterly, 2025-06-30) — Amortization: 14322000.00
PCRX income_statement (quarterly, 2025-06-30) — Amortization Of Intangibles Income Statement: 14322000.00
PCRX income_statement (quarterly, 2025-06-30) — Average Dilution Earnings: 0.00
PCRX income_statement (quarterly, 2025-06-30) — Basic Average Shares: 45459000.00
PCRX income_statement (quarterly, 2025-06-30) — Basic EPS: -0.11
PCRX cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 283610000.00
PCRX cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -2697000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 50911000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Capital Stock: 48000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 300484000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 445864000.00
PCRX cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -57505000.00
PCRX cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 62163000.00
PCRX cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 12012000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 6880000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -19377000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Inventory: -14399000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: 9823000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Payable: 6880000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -12497000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -13434000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Receivables: -9605000.00
PCRX cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -40112000.00
PCRX cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -9605000.00
PCRX cash_flow (quarterly, 2025-06-30) — Changes In Cash: 16670000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Common Stock: 48000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 757767000.00
PCRX cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -50039000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 9632000.00
PCRX income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 40866000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 71023000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Current Assets: 745613000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 9620000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Current Debt: 202397000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 212017000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 313164000.00
PCRX cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: 752000.00
PCRX cash_flow (quarterly, 2025-06-30) — Deferred Tax: 752000.00
PCRX cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 27322000.00
PCRX income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 14322000.00
PCRX cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 27322000.00
PCRX income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 14322000.00
PCRX income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 45459000.00
PCRX income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.11
PCRX income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — EBIT: 1919000.00
PCRX income_statement (quarterly, 2025-06-30) — EBITDA: 29241000.00
PCRX cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 204000.00
PCRX cash_flow (quarterly, 2025-06-30) — End Cash Position: 300484000.00
PCRX cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -57505000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Finished Goods: 96151000.00
PCRX cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 9315000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 4062000.00
PCRX income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 37614000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Goodwill: 20300000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 442863000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Gross PPE: 354481000.00
PCRX income_statement (quarterly, 2025-06-30) — Gross Profit: 140233000.00
PCRX cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 7947000.00
PCRX income_statement (quarterly, 2025-06-30) — Interest Expense: 3846000.00
PCRX income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 3846000.00
PCRX income_statement (quarterly, 2025-06-30) — Interest Income: 5008000.00
PCRX income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 5008000.00
PCRX cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 4972000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Inventory: 148163000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Invested Capital: 1338259000.00
PCRX cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 62163000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 18810000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Leases: 97408000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 41291000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 378095000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 419386000.00
PCRX cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -3750000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 200913000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: 0.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -50039000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Net Debt: 280008000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Income: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -4847000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -4847000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Interest Income: 313000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 64860000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -3750000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -3750000.00
PCRX income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 313000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -5285000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Net PPE: 201706000.00
PCRX cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -2697000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 314904000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 128270000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 4583000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 128270000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 4583000.00
PCRX income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 29875000.00
PCRX income_statement (quarterly, 2025-06-30) — Normalized Income: -4346140.00
PCRX cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 12012000.00
PCRX income_statement (quarterly, 2025-06-30) — Operating Income: 9133000.00
PCRX income_statement (quarterly, 2025-06-30) — Operating Revenue: 181099000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 46304667.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 37219000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 202397000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 4062000.00
PCRX income_statement (quarterly, 2025-06-30) — Other Gand A: 26231000.00
PCRX income_statement (quarterly, 2025-06-30) — Other Income Expense: -11373000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 422563000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Investments: 18810000.00
PCRX cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 2425000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 42362000.00
PCRX income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -10739000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Properties: 46528000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 145380000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Payables: 30124000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 101147000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
PCRX income_statement (quarterly, 2025-06-30) — Pretax Income: -1927000.00
PCRX cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 1569000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
PCRX cash_flow (quarterly, 2025-06-30) — Purchase Of Business: 0.00
PCRX cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -6306000.00
PCRX cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -2697000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Raw Materials: 40932000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Receivables: 114367000.00
PCRX income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 27866000.00
PCRX income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 27322000.00
PCRX cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -3750000.00
PCRX cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -50039000.00
PCRX income_statement (quarterly, 2025-06-30) — Research And Development: 28200000.00
PCRX income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 634000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -206391000.00
PCRX income_statement (quarterly, 2025-06-30) — Salaries And Wages: 11383000.00
PCRX cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 71166000.00
PCRX income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 50964000.00
PCRX income_statement (quarterly, 2025-06-30) — Selling General And Administration: 88578000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Share Issued: 46304667.00
PCRX income_statement (quarterly, 2025-06-30) — Special Income Charges: -634000.00
PCRX cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 15472000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 757767000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 314904000.00
PCRX income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -133140.00
PCRX income_statement (quarterly, 2025-06-30) — Tax Provision: 2920000.00
PCRX income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
PCRX balance_sheet (quarterly, 2025-06-30) — Total Assets: 1537262000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 1135862000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Total Debt: 631403000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 757767000.00
PCRX income_statement (quarterly, 2025-06-30) — Total Expenses: 171966000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 779495000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 791649000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 466331000.00
PCRX income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 8499000.00
PCRX income_statement (quarterly, 2025-06-30) — Total Other Finance Cost: 849000.00
PCRX income_statement (quarterly, 2025-06-30) — Total Unusual Items: -634000.00
PCRX income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -634000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 2792829.00
PCRX balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 75515000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Work In Process: 11080000.00
PCRX balance_sheet (quarterly, 2025-06-30) — Working Capital: 432449000.00
PCRX income_statement (quarterly, 2025-09-30) — +Operating Expense: 132085000.00
PCRX income_statement (quarterly, 2025-09-30) — +Total Revenue: 179516000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 17687000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 115268000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -132665000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1049545000.00
PCRX income_statement (quarterly, 2025-09-30) — Amortization: 14322000.00
PCRX income_statement (quarterly, 2025-09-30) — Amortization Of Intangibles Income Statement: 14322000.00
PCRX cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 25866000.00
PCRX income_statement (quarterly, 2025-09-30) — Basic Average Shares: 44038000.00
PCRX income_statement (quarterly, 2025-09-30) — Basic EPS: 0.12
PCRX cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 300484000.00
PCRX cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -3870000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 48587000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Capital Stock: 48000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 147589000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 246334000.00
PCRX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -257476000.00
PCRX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 43614000.00
PCRX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 60834000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -12013000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 7530000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Inventory: -9513000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -5826000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Payable: -12013000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -4483000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 4724000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Receivables: -897000.00
PCRX cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -15995000.00
PCRX cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -897000.00
PCRX cash_flow (quarterly, 2025-09-30) — Changes In Cash: -153028000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Common Stock: 48000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 727214000.00
PCRX cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -50041000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 11785000.00
PCRX income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 34278000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 79643000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Current Assets: 562751000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 9748000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 9748000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 107078000.00
PCRX cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: 8072000.00
PCRX cash_flow (quarterly, 2025-09-30) — Deferred Tax: 8072000.00
PCRX cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 21191000.00
PCRX income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 14322000.00
PCRX cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 21191000.00
PCRX income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 14322000.00
PCRX income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 44459000.00
PCRX income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.12
PCRX income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — EBIT: 13177000.00
PCRX income_statement (quarterly, 2025-09-30) — EBITDA: 34368000.00
PCRX cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 133000.00
PCRX cash_flow (quarterly, 2025-09-30) — End Cash Position: 147589000.00
PCRX cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -257476000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Finished Goods: 92412000.00
PCRX cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 56964000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 4123000.00
PCRX income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 33326000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Goodwill: 20317000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 402713000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Gross PPE: 324319000.00
PCRX income_statement (quarterly, 2025-09-30) — Gross Profit: 145238000.00
PCRX income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 25866000.00
PCRX cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 711000.00
PCRX income_statement (quarterly, 2025-09-30) — Interest Expense: 3653000.00
PCRX income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 3653000.00
PCRX income_statement (quarterly, 2025-09-30) — Interest Income: 8534000.00
PCRX income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 8534000.00
PCRX cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 2703000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Inventory: 157680000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Invested Capital: 1103935000.00
PCRX cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 43614000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 20271000.00
PCRX cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 101000000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Leases: 76343000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 38839000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 376721000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 415560000.00
PCRX cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: 101000000.00
PCRX cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -306236000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 191925000.00
PCRX cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
PCRX cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -50041000.00
PCRX balance_sheet (quarterly, 2025-09-30) — Net Debt: 229132000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Income: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 5432000.00
PCRX income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 5432000.00